Lyme Disease Vaccine Candidate Proven Safe in Children
A clinical trial found the LB6V vaccine candidate was well tolerated among participants aged 5 to 17 years old.
Updated on Oct. 6, 2026 in Children’s Health
Live Poll
Would you trust the safety results of a new vaccine study for your children?
Results presented on October 6, 2026, confirmed that the investigational Lyme disease vaccine candidate LB6V is safe for children and adolescents. The findings were derived from a randomized clinical trial that concluded data collection on July 21, 2025.
Why it matters
Developing a safe vaccine for children is a critical step in addressing the increasing public health burden of Lyme disease. The study demonstrates that the vaccine candidate does not pose significant safety risks compared to a placebo in pediatric populations.
The study included 3,547 participants across 57 sites in the United States. While 89.1% of vaccine recipients experienced local reactions compared to 44.5% of the placebo group, serious adverse event rates remained identical between both cohorts.
The players
American Academy of Pediatrics
This is a professional association of pediatricians dedicated to the health and well-being of infants, children, and adolescents.
The details
Participants were randomized at a 3:1 ratio to receive either the LB6V vaccine or a saline placebo over a 4-dose series. Researchers monitored for adverse events, noting that withdrawals due to such events were rare, occurring in 0.8% of the vaccine group and 0.6% of the placebo group.
Timeline
Trial enrollment and data collection began on December 12, 2022.
Trial data collection concluded on July 21, 2025.
Study results were presented on October 6, 2026.
Health Landscape
This study aligns with the rigorous standards for pediatric immunization development upheld by the American Academy of Pediatrics. It marks a departure from historical gaps in preventative research for tick-borne diseases specifically targeting younger populations.
This news indicates that progress is being made toward a potential future preventative option for children living in areas with high tick activity. Parents should consult their primary care providers for updates on pediatric Lyme disease prevention until further efficacy data is released.
The takeaway
The successful safety profile of the LB6V candidate provides a foundation for the next stages of clinical development. Families in endemic areas can expect further research into efficacy as the medical community works toward a preventative solution.
Further reading
For more information on pediatric immunization standards, visit the Children’s Health section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Would you trust the safety results of a new vaccine study for your children?
